Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 5kWORD 17k
14 November 2018
E-004528/2018(ASW)
Answer given by Mr Andriukaitis on behalf of the European Commission
Question reference: E-004528/2018

The Commission notes that the European Medicines Agency (EMA), like other EU actors, has prepared business continuity plans to address certain consequences stemming from the United Kingdom leaving the Union. For more information on these plans, the Commission invites the Honourable Member to directly address the Agency.

The Commission notes from the Agency's plans that core activities related to the evaluation, maintenance and supervision of medicines, including its activities on Anti-Microbial Resistance (AMR) are currently being safeguarded and that therefore the Agency is continuing its contribution to the fight against AMR both at international and European level.

The Commission will continue its collaboration with international partners in order to meet the AMR Action Plan's objectives(1). It will also support EMA in the implementation of its strategy to modernise the Summary of Product Characteristics of old Antibiotics(2).

(1)https://ec.europa.eu/health/amr/sites/amr/files/amr_action_plan_2017_en.pdf
(2)https://www.ema.europa.eu/human-regulatory/marketing-authorisation/product-information/how-prepare-review-summary-product-characteristics

Last updated: 14 November 2018Legal notice